A primer of bone metastases management in breast cancer patients

B. Petrut MD, M. Trinkaus MD, C. Simmons MD, and M. Clemons MB BS MD

ABSTRACT

Bone is the most common site for distant spread of breast cancer. Following a diagnosis of metastatic bone disease, patients can suffer from significant morbidity because of pain and skeletal related events (SREs). Bisphosphonates are potent inhibitors of osteoclastic function and the mainstay of bone-directed therapy for bone metastases. The aims of bisphosphonates are to prevent and delay SREs, to reduce bone pain, and to improve quality of life. Bisphosphonate therapy appears to have revolutionized treatment of bone metastases, but bisphosphonate use has several limitations. Those limitations include the high cost of the agents and the need for return trips to the clinic for intravenous treatment. Moreover, many uncertainties surround bisphosphonate use—for example, the timing of bisphosphonate initiation, the choice of bisphosphonate to use, the optimal duration of treatment, and the appropriate means to identify patients who will and will not benefit. In addition, potentially serious adverse effects have been associated with bisphosphonate use—for example, renal toxicity, gastrointestinal side effects, and osteonecrosis of the jaw. The present review is intended as a primer for oncology specialists who treat patients with bone metastases secondary to breast cancer. It focuses on bisphosphonate treatment guidelines, the evidence for those guidelines, and a discussion of new therapeutic agents. It also discusses the use of biochemical markers of bone metabolism, which show promise for predicting the risk of a patient’s developing a SRE and of benefiting from bisphosphonate treatment.

KEY WORDS

Bone metastases, breast cancer, skeletal-related events, bisphosphonate

1. INTRODUCTION

Bone is the most common site of breast cancer recurrence. Despite modern cancer therapy, up to two thirds of patients with bone metastasis will subsequently develop an skeletal-related event (SRE), defined as any of pathologic fracture, a requirement for surgical intervention and palliative radiotherapy to bone lesions, hypercalcemia of malignancy, and spinal cord compression. Not only are SREs associated with significant morbidity, they also negatively affect survival. Moreover, SREs are associated with loss of mobility and social functioning, and reduction in quality of life (QOL).

Treatment of bone metastases ideally involves a multidisciplinary team, including medical oncologists, radiation oncologists, palliative care specialists, and orthopedic surgeons. Systemic treatment aimed at delaying the progression of bone metastases may include endocrine therapy, biologic agents, chemotherapy, and oral or intravenous bisphosphonate therapy. New osteoclast inhibitors are currently under investigation and may offer alternative treatment options for these patients in the future.

2. BISPHOSPHONATES

Bisphosphonates are an established standard of care for patients with bone metastases. Table I reviews the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario guidelines regarding bisphosphonate use in breast cancer patients with bone metastases. Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption through several mechanisms, including induction of osteoclast apoptosis, inhibition of osteoclast maturation and differentiation, and reduced osteoclast activity. In addition, bisphosphonates may act directly on tumour cells by inducing apoptosis, inhibiting matrix metalloproteinase 1, inhibiting angiogenesis, decreasing adhesion of tumour cells within bone, and reducing levels of vascular endothelial growth factor.

2.1 Bisphosphonate Trials and Meta-analyses

The clinical benefits of bisphosphonate therapy in secondary prophylaxis (that is, their use in patients with breast cancer and established bone metastases) have been demonstrated in a large number of pla-
The presence or absence of bone pain should not appear to improve overall survival. 21. 95% CI: 0.78 to 0.89; confidence interval (CI): 0.64 to 0.99], combined fractures (OR: 0.75; 95% CI: 0.61 to 0.93), need for radiotherapy (OR: 0.65; 95% CI: 0.54 to 0.79), need for orthopedic surgery (OR: 0.59; 95% CI: 0.43 to 0.83), and hypercalcemia (OR: 0.43; 95% CI: 0.29 to 0.63), but not for spinal cord compression. 20. Similarly, in a Cochrane systematic review that included twenty-one randomised studies involving bisphosphonate use among breast cancer patients 21, nine of those studies demonstrated a risk reduction (RR) of 17% (RR: 0.83; 95% CI: 0.78 to 0.89; p < 0.00001) for developing a SRE with bisphosphonate use. Intravenous zoledronic acid 4 mg was most effective in reducing the risk of developing a SRE by 41% (RR: 0.59; 95% CI: 0.42 to 0.82). In seven of the studies, bisphosphonates, when compared with placebo, significantly improved bone pain. 21.

The benefits of bisphosphonate therapy for various SRES seem to be time-dependent; that is, the bisphosphonate must be given for at least 6 months before an effect is seen on skeletal morbidity outcomes and for at least 12 months before a reduction in the need for orthopedic surgery becomes significant. 20. To date, treatment with bisphosphonate does not appear to improve overall survival. 21.

Results from clinical trials evaluating the analgesic properties of bisphosphonates vary considerably, mostly because of differences in the patient populations and pain assessment scales. 22, 23 Placebo-controlled trials of intravenous pamidronate, ibandronate, and zoledronic acid have demonstrated improvement in pain scores. 7, 12, 22 Two published comparative trials have reported an advantage for intravenous pamidronate over oral clodronate in reducing metastatic bone pain. 24. A systemic review by Wong and Wiffen concluded that although evidence supported bisphosphonate effectiveness in providing some pain relief for bone metastasis, the data were insufficient to recommend bisphosphonates as first-line therapy for metastasis-related bone pain. 25. New strategies of bisphosphonate administration for bone pain are currently being explored. 26.

Bisphosphonates are remarkably variable in structure and potency. The newer, nitrogen-containing bisphosphonates such as ibandronate, pamidronate, and zoledronic acid are several orders of magnitude more potent than earlier-generation bisphosphonates such as clodronate. 27. Comparative bisphosphonate trials have attempted to ascertain the superiority of one bisphosphonate regimen over another, with endpoints being reduction in the incidence of SRES and improvement of pain and QOL (Table III). One study showed that pamidronate was superior to clodronate with regard to pain (p < 0.01) and improvement in biochemical markers of bone turnover. 24. Another trial demonstrated the superiority of zoledronic acid (4 mg intravenously over 15 minutes) over pamidronate (90 mg intravenously over 2 hours); patients treated with zoledronic acid had an increased time to first SRE (p = 0.013) and fewer SRES (p = 0.58). 29. In that

| TABLE 1 American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) guidelines for bisphosphonate (BP) use in bone-metastatic disease in breast cancer patients. 3, 4 |
|-------------------------------------------------|-------------------------------------------------|
| **Recommended BP**                              | **ASCO (2003 update)**                          |
| Treatment with BP s to be continued until evidence appears of substantial decline in the patient’s performance status. |
| **Initiation of BP for prevention of skeletal-related events** | **ASCO (2003 update)**                          |
| Treatment with BP s in women with normal plain radiographs who demonstrate bone destruction in other imaging. Starting BP s in women with only an abnormal bone scan but without evidence of bone destruction is not recommended. |
| **Role in pain management**                     | **ASCO (2003 update)**                          |
| The presence or absence of bone pain should not be a factor in initiating BP s. |
| **Discontinuation**                             | **ASCO (2003 update)**                          |
| Treatment with BP s to be continued until evidence of substantial decline in the patient’s performance status. |
| **ccO (2004 update)**                           |                                                  |
| Oral clodronate, intravenous pamidronate, or zoledronic acid. |
| Recommendations for BP s are not restricted to patients with osteolytic metastases. |
| All women with breast cancer who have bone metastases should be offered BP s. |
| An exception should be women with a short expected survival (that is, less than 6 months), who have well-controlled bone pain. |
| In patients with bone metastases and pain, treatment with pamidronate, zoledronic acid, or clodronate may be a useful adjunct to conventional measures for pain control. |
| No evidence from clinical trials addresses the optimal duration of BP use. |
### TABLE II Overview of placebo-controlled trials of bisphosphonates in advanced breast cancer

| Trial                  | Bisphosphonate | Dose                  | Results                                                                 |
|------------------------|----------------|-----------------------|-------------------------------------------------------------------------|
| Paterson et al., 1993  | Clodronate     | Oral, 1600 mg daily   | Reduced the event rate of vertebral fractures and deformity, and the combined event rate for all events. |
| Kristensen et al., 1999| Clodronate     | Oral, 400 mg twice daily | Reduced the number and significantly delayed the time to first SRE.         |
| Tubiana–Hulin et al., 2001 | Clodronate   | Oral, 1600 mg daily   | Significantly delayed the time to first bone event and significantly reduced pain intensity and analgesic use. |
| Hortobagyi et al., 1998 | Pamidronate   | Intravenous, 90 mg every 3–4 weeks | Reduced the incidence and delayed the onset of SREs.                    |
| Theriault et al., 1999  | Pamidronate   | Intravenous, 90 mg every 4 weeks | Reduced skeletal morbidity and the incidence of SREs and delayed the onset of SREs. |
| Lipton et al., 2000     | Pamidronate   | Intravenous, 90 mg every 3–4 weeks | Reduction in the percentage of patients with >1 SRE, median time to first SRE extended by nearly 6 months, and reduction in the mean skeletal morbidity rate was found. |
| Hultborn et al., 1999   | Pamidronate   | Intravenous, 60 mg every 4 weeks | Significantly fewer SREs                                                 |
| Conte et al., 1996      | Pamidronate   | Intravenous, 45 mg every 3 weeks | Effective in delaying the time to progression of bone lesions.            |
| Body et al., 2003       | Ibandronate   | Intravenous, 2 or 6 mg every 3–4 weeks | Significantly reduced the SMPR by 20% and extended the time to first SRE. |
| Body et al., 2004       | Ibandronate   | Orally, 50 mg daily   | Significantly reduced the SMPR as compared with placebo in a combined analysis. |
| Tripathy et al., 2004   | Ibandronate   | Orally, 20 mg or 50 mg daily | Significantly reduced the SMPR as compared with placebo.                  |
| Kohno et al., 2005      | Zoledronic acid| Intravenous, 4 mg every 4 weeks | Significant multiple event analysis demonstrated a 44% reduction in the risk of developing a SRE. |

SRE = skeletal-related event; SMPR = skeletal morbidity period rate.

### TABLE III Overview of completed comparative trials of bisphosphonates in bone metastases

| Trial                  | Patients | Bisphosphonate | Primary outcome | Conclusions                                                                 |
|------------------------|----------|----------------|-----------------|-----------------------------------------------------------------------------|
| Jagdev et al., 2001    | n=51 [various primary cancers (22 breast)] | Clodronate: Oral, 1600 mg daily (group 1) Intravenous, 1500 mg loading, then oral 1600 mg daily (group 2) Pamidronate: Intravenous, 90 mg every 3 weeks (group 3) | Use pain scores and NTX to compare efficacy of two schedules of clodronate with intravenous pamidronate | Pamidronate was more effective than clodronate with regard to pain control ($p<0.01$). No statistically significant difference in NTX evident between groups. |
| Rosen et al., 2002     | n=1648 (myeloma and breast cancer) | Zoledronic acid: Intravenous infusion, 4 mg or 8 mg over 15 minutes Pamidronate: Intravenous infusion, 90 mg over 2 hours every 3–4 weeks | Use skeletal-related events (SRES) and pain score to compare efficacy of zoledronic acid with that of pamidronate | In subgroup of breast cancer patients ($n=1130$), zoledronic acid had significant clinical benefit as compared with pamidronate: prolonged time to first SRE, 310 days vs. 174 days, $p=0.013$; and reduced incidence of SRES, mean 1.2 vs. 2.4 events per year, $p=0.008$. |

NTX = N-terminal crosslinked type 1 collagen telopeptide.
study, the proportion of patients with at least 1 SRE was similar for zoledronic acid and pamidronate, but zoledronic acid reduced by 20% the overall risk of any skeletal complications developing \((RR: 0.799; p = 0.025)\) \(^{29}\). When phase \(\text{III}\) trial data are compared, ibandronate and zoledronic acid seem to have similar efficacy \(^{30}\). That hypothesis is currently being tested in two large randomized phase \(\text{III}\) trials (Table IV) \(^{31,32}\).

2.2 Uncertainties About Bisphosphonate Use in Clinical Practice

The evidence of clinical benefit from bisphosphonates in breast cancer is overwhelming. Attention is now concentrated on defining the optimal time to start treatment, duration of treatment, and importantly, predicting which patients are most likely to benefit from either repeat bisphosphonate administration or a switch to an alternative bisphosphonate \(^{33}\) (Table V).

2.3 Which Patients Benefit Most from Bisphosphonate Use?

Randomized controlled trials have shown that the beneficial effects of bisphosphonates are time-dependent; significant benefits were seen only after 6 months of treatment \(^{20}\). Therefore, looking at survival times for patients with breast cancer is important before starting them on bisphosphonate treatment.

A retrospective analysis involving 859 patients who developed bone metastases from breast cancer showed that, as compared with patients with bone and visceral metastases, patients with disease confined to the skeleton were most likely to develop a SRE \(^{34}\). The difference with regard to the development of a SRE was probably attributable to the survival difference between the groups (median survival for patients with bone-only disease was 2.2 years as compared with 5.5 months for patients with bone and liver metastases). Patients with bone-only disease may therefore benefit most from treatment with bisphosphonates, because they are most likely to live long enough to experience the time-dependent benefits of bisphosphonates \(^{34}\). Notably, Canadian treatment guidelines do not encourage the use of bisphosphonate treatment in patients with a life expectancy below 6 months and who are asymptomatic from their bone metastases \(^{3}\).

Along the same lines, most bisphosphonate trials have enrolled a disproportionate number of patients with bone-only disease who, as a consequence of their prolonged survival, are at greater risk of developing SRES than are patients with (for example)

| TABLE IV | Overview of ongoing comparative trials of bisphosphonates in metastatic breast cancer |
|-----------|-----------------------------------------------|
| Trial                                               | Patients (n) | Bisphosphonate | Duration of study | Primary outcome | Secondary outcomes |
| Southwest Oncology Group S0308 \(^{31}\)            | 488          | Ibandronate: oral, 50 mg daily vs. Zoledronic acid: intravenous, 4 mg every 4 weeks | 18 Months | New skeletal-related event (SRE) | Time to first SRE, quality of life, overall survival, safety |
| Zoledronicate versus Ibandronate Comparative Evaluation \(^{32}\) | 1400         | Ibandronate: oral, 50 mg daily vs. Zoledronic acid: intravenous, 4 mg every 4 weeks | 96 Weeks of treatment with follow-up for further 3 years | Multiple event analysis: SRES over 96 weeks | Proportion of patients experiencing new SRE, time to first event, quality of life, safety |

| TABLE V  | Summary of bisphosphonate use for metastatic bone disease in breast cancer patients |
|-----------|-----------------------------------------------|
Placebo-controlled trials in breast cancer patients with bone metastases confirm significant reductions in the incidence and delay in the occurrence of skeletal-related events (SRES) with bisphosphonate use.

Effects of bisphosphonates are time-dependent; in terms of reducing SRES, benefits begin to be identified after 6 months of treatment. The benefits of bisphosphonate treatment in patients with poor prognosis are mostly unknown.

Which bisphosphonate to use as first-line therapy remains to be clarified. Evidence mainly supports the use of intravenous aminobisphosphonates. However, clodronate can be offered to patients who are unable or unwilling to come to hospital for intravenous treatment.

The absolute magnitude of bisphosphonate benefit and the who, when, and how long parameters of treatment remain unclear.

A switch to a more potent bisphosphonate (zoledronic acid or ibandronate) after either a SRE or bone metastasis progression during treatment with a first-line bisphosphonate (clodronate or pamidronate) may offer better pain control.
visceral disease. Therefore, the magnitude of the bene
fit seen in bisphosphonate trials probably exceeds
the benefit seen in clinical practice. Tables II and III
provide an overview of placebo-controlled trials and
comparative trials of bisphosphonate use in patients
with bone metastases.

Further prospective studies are needed to iden
tify the subgroup of patients most likely to develop
SREs and therefore to benefit most from bisphos-
phonate treatment. In an attempt to develop a prediction
model, our group is currently analyzing baseline clin-
ic characteristics in 100 patients on bisphosphonates
at three cancer centers 35.

2.4 When Should Bisphosphonates Be Started in
Patients with Newly Diagnosed Bone
Metastases?

There is a paucity of data for optimal use of
bisphosphonates, mainly in regard to initiation and
treatment duration. According to ASCO guidelines, bis-
phosphonate therapy should be started in patients with
metastatic breast cancer who have imaging evidence
of lytic bone destruction. Furthermore, ASCO consid-
ers it “reasonable” to start intravenous bisphos-
phonates in breast cancer patients with an abnormal
bone scan despite normal plain radiographs, provided
that the patients are reporting concordant localized
pain. Intravenous bisphosphonate treatment is not rec-
commended for asymptomatic patients with abnormal
bone scans whose plain radiographs are normal 4.
Canadian guidelines do not restrict the indications
for bisphosphonate therapy to patients with lytic bone
destruction on imaging 3. Despite these recommenda-
tions, most trials suggest that, given the potential of
bisphosphonates to delay time to first SRE, bisphosphonates
should be started when bone me-
tastases are diagnosed, even when patients are asym-
tomatic 21,27.

3. CHOOSING A BISPHOSPHONATE

Current Cancer Care Ontario guidelines advocate
starting patients with newly diagnosed bone me-
tastases on intravenous pamidronate or oral
clofrodronate as first-line treatment. In other North
American centers and in Europe, most patients with
breast cancer metastatic to bone are started on
zoledronic acid as first-line treatment 36.

Oral clodronate is approved for patients with
breast cancer, and it should be considered for patients
who cannot attend frequent clinic appointments or
who choose to decline intravenous therapy. The effi-
cacy of clodronate in preventing skeletal morbidity
has been shown in placebo–controlled clinical trials
of women with lytic bone disease (Table II) 8–10. How-
ever, in clinical practice, the potential for adverse
gastrointestinal effects and the very low absorption
rates (<5%) of oral clodronate even under ideal con-
ditions may contribute to poorer outcomes and poor
patient compliance 27.

Comparative trials have shown the superiority of
pamidronate over clodronate for pain control, and the
superiority of zoledronic acid over pamidronate for
delaying the first SRE and reducing the incidence of
SREs (Table III). Ongoing comparative studies are try-
ing to clarify which bisphosphonate is best to use in
clinical practice (Table IV). Interestingly, in one study,
patients receiving oral ibandronate after prior intra-
venous pamidronate significantly preferred the oral
regimen 30.

4. OPTIMAL DURATION OF
BISPHOSPHONATE TREATMENT

The ASCO guidelines recommend that bisphosphonate
treatment continue until there is evidence of a sub-
stantial decline in a patient’s general performance sta-
tus (Table I). A recent Canadian study confirmed that
90% of patients continue bisphosphonate treatment
until death, despite repeated SREs and bone progres-
sion 37. Criteria to guide response to bisphosphonate
therapy and the optimal and appropriate duration of
bisphosphonate administration are lacking. The deci-
sion to continue, stop, or switch to an alternative bis-
phosphonate remains empirical and based on personal
experience. Studies have shown that patients with skel-
etal disease progression and pain despite the use of
oral clodronate or intravenous pamidronate may
achieve an improvement in pain control and a reduc-
tion in levels of bone turnover markers after switch-
ing from pamidronate to zoledronic acid or to
ibandronate 30,38. Our group is starting a phase III trial
to define the role of, and best time to switch patients
to, a more potent bisphosphonate treatment after ei-
ther bone disease progression or development of a SRE
while on first-line bisphosphonate treatment 39.

Unfortunately, despite treatment with even the
most potent bisphosphonate (zoledronic acid), one
third of patients will develop further SREs within
2 years of initiating therapy. In addition, bisphos-
phonate side effects such as renal toxicity, nausea, vomit-
ing, flu-like symptoms, and osteonecrosis of the jaw
are becoming increasingly prominent concerns as the
use of these agents continues to increase 40,41. Further-
more, bisphosphonates are expensive agents; they have
a substantial impact on the oncology drug budget. In
a post hoc economic assessment of two multinational
trials, the cost of pamidronate was projected to greatly
exceed the cost savings associated with preventing a
SRE 40. However, a cost–utility analysis performed in
Canada of prophylactic pamidronate for prevention
of SREs suggested that pamidronate offered breast can-
cer patients with bone metastases a substantial qual-
ity–adjusted benefit at a reasonable cost 42.

The existing cost-effectiveness data are difficult
to apply across different health care systems 43. Im-
portantly, maintaining patients on bisphosphonate
treatment indefinitely has major financial implications with unknown benefits. Pharmacoeconomic evaluations should be therefore combined with clinical trials to accurately predict the true cost of this supportive treatment and, ultimately, to assess the optimal use of these agents.

5. MARKERS OF BONE RESORPTION

In recent years, advances in understanding the mechanism of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. The most widely used markers are urinary N-terminal crosslinked type 1 collagen telopeptide (NTX) and C-terminal cross-linked type 1 telopeptide. Urinary NTX levels have been shown to predict occurrence of SREs in breast cancer patients with bone metastases, response to bisphosphonates, pain scores, and patient outcomes.

Several studies have shown a strong correlation between moderate (50–100 nmol/mmol creatinine) and high (≥ 100 nmol/mmol creatinine) levels of NTX and the number of SREs or deaths (or both) in patients with bone metastasis.

Furthermore, NTX seem to be valuable in assessing how pain responds to bisphosphonates. In the pooled analysis of phase III trials of zoledronic acid, significant reductions in NTX were accompanied by significant declines in bone-pain scores and lesser increases in analgesic use at 96 weeks. Our own group conducted a study with breast cancer patients that showed a reduction in NTX levels after patients on a second-generation bisphosphonate were switched to a third-generation bisphosphonate after development of a SRE or progressive bone disease. The decline in NTX levels was an important predictor for palliative pain response to both ibandronate and zoledronic acid.

Overall, the hope is that biochemical markers will serve as adequate surrogates for further assessment of bisphosphonate efficacy. However, given the lack of sufficient, rigorous phase III data, current ASCO guidelines advise against the use of biochemical markers to monitor bisphosphonate treatment routinely. The role of bone markers in guiding bisphosphonate treatment is currently being tested in a large National Cancer Research Institute–supported phase III clinical trial in the United Kingdom (BISMARK, n = 1400). In that trial, patients with breast cancer–associated bone metastases are being treated with zoledronic acid, either on a regular schedule of 4 mg intravenously every 3–4 weeks, or as indicated by NTX levels. The primary endpoint is development of a SRE. Secondary endpoints include QOL, pain, analgesic use, health economics, change in systemic therapy, and survival.

6. NEW AGENTS TARGETING THE MECHANISM OF BONE METASTASES

In metastatic bone disease, an imbalance occurs between the action of osteoblasts and that of osteoclasts, with net bone loss resulting. A triad of molecules has been shown to regulate the maturation, differentiation, and survival of osteoclasts:

- receptor activator of nuclear factor κB (RANK),
- RANK ligand (RANKL), and
- osteoprotegerin (OPG).

The RANKL/OPG ratio is significantly increased in patients with severe osteolytic bone metastases. Therefore, targeting the RANK–RANKL–OPG pathway is a promising intervention for treating metastatic bone disease, particularly among patients who are refractory to potent bisphosphonates.

Denosumab (AMG 162) is a human monoclonal antibody that binds to and inhibits RANKL with high affinity and specificity, mimicking the effect of endogenous OPG. A recent phase II study of patients with bone metastases showed that, as compared with pamidronate, denosumab is significantly more likely to suppress urinary NTX. A phase III trial comparing denosumab with zoledronic acid is ongoing in patients with bone metastases.

7. SUMMARY

Many systemic therapeutic options are available for patients with bone metastases, with none being completely satisfactory. Bisphosphonates have become the mainstay of practice, and their use in breast cancer patients with bone metastases is associated with a significant reduction and delay in SREs and a reduction in bone pain. Despite the rapid integration of bisphosphonates into standard clinical practice, many uncertainties remain regarding their use: for example, the optimal bisphosphonate agent and duration of therapy, the most beneficial scheduling regimen, and identification of the patients most likely to benefit from bisphosphonate treatment.

Currently, Cancer Care Ontario guidelines advocate for the use of intravenous pamidronate or oral clodronate for patients with metastatic bone disease secondary to breast cancer. Zoledronic acid is largely reserved for clinical trials or for patients who are intolerant to intravenous pamidronate. Meanwhile,
elsewhere in North America and Europe, zoledronic acid is first-line therapy for metastatic bone disease among breast cancer patients.

Further research is merited to identify factors that accurately predict the subgroups of patients at highest risk for developing bone metastases and subsequent complications and the patients that will benefit most from bisphosphonate treatment. Markers of bone turnover seem to hold the most promise for identifying patients likely to benefit from bisphosphonate treatment and for guiding the decision to discontinue bisphosphonate therapy or to switch to an alternative bisphosphonate. Finally, new osteoclast inhibitors are currently under investigation, and these agents may offer effective treatment options with reduced toxicity for patients with bone metastases.

8. REFERENCES

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 2006;12:6243–8.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. *Br J Cancer* 1987;55:61–6.
3. Warr D, Johnston M. Use of bisphosphonates in women with breast cancer. Practice guideline report no. 1-11. Hamilton, ON: Cancer Care Ontario, Program in Evidence-Based Care; 2004. [Available online at: www.cancercare.on.ca/pdfs/pebc1-11f.pdf; cited December 10, 2007]
4. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003;21:4042–57.
5. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. *Nat Clin Pract Oncol* 2007;4:42–55.
6. Coleman RE. Bisphosphonates in breast cancer. *Ann Oncol* 2005;16:687–95.
7. Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. *Ann Oncol* 2007;18:1165–71.
8. Kristensen B, Ejlersen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. *J Intern Med* 1999;246:67–74.
9. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. *J Clin Oncol* 1993;11:59–65.
10. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [French]. *Bull Cancer* 2001;88:701–7.
11. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. *J Clin Oncol* 1998;16:2038–44.
12. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. *J Clin Oncol* 2005;23:314–21.
13. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 1B Aredia Breast Cancer Study Group. *J Clin Oncol* 1999;17:846–54.
14. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. *Cancer* 2000;88:1082–90.
15. Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. *Anticancer Res* 1999;19:3383–92.
16. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. *J Clin Oncol* 1996;14:2552–9.
17. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. *Ann Oncol* 2003;14:1399–05.
18. Body JJ, Diel IJ, Lichinitser M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. *Br J Cancer* 2004;90:1133–7.
19. Tripathy D, Lichinitser M, Lazarev A, et al. on behalf of the MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. *Ann Oncol* 2004;15:743–50.
20. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. *BMJ* 2003;327:469.
21. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. *Cochrane Database Syst Rev* 2005;:CD003474.
22. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. *Support Care Cancer* 2006;14:408–18.
23. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. *J Pain Symptom Manage* 2007;33:462–72.
24. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. *Ann Oncol* 2001;12:1433–8.
25. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. *Cochrane Database Syst Rev* 2002;CD002068.
26. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. *J Clin Oncol* 2004;22:3587–92.
27. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the...
use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;[in press]. [2007;(Epub ahead of print)]

28. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–87.

29. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735–44.

30. Clemons M, Dranitsaris G, Ooi W, Cole DE. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphate (BP) therapy. Breast Cancer Res Treat 2008;[in press]. [2007;(Epub ahead of print)]

31. Rivkin S. Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG 0308 trial [abstract]. Bone 2006;38(suppl 1):S82.

32. Barrett–Lee P, Murray N. Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the ncri zice trial [abstract]. Bone 2006;38(suppl 1):S57.

33. Clemons M, Dranitsaris G, Cole D, Gainford MC. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 2006;11:227–33.

34. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 2000;36:476–82.

35. Clemons M, Cole DE, Gainford MC. Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat 2006;97:81–90.

36. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9(suppl 4):14–27.

37. Verma S, Kerr–Cresswell D, Dranitsaris G, et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer 2004;12:852–8.

38. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24:4895–900.

39. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769–73.

40. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18:72–9.

41. Bamias A, Kazantzis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580–7.

42. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271–9.

43. Botteman M, Barghout V, Stephens J, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072–82.

44. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031–7.

45. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243–50.

46. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002;94:2521–33.

47. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925–35.

48. Lipton A, Cook R, Coleman RE, et al. Normalization of bone markers and improved survival during zoledronic acid therapy [abstract]. Proc Am Soc Clin Oncol 2007;25:9013.

49. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88(suppl):2892–8.

50. Lipton A, Alvarado A, De Boer R, et al. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP) [abstract]. Proc Am Soc Clin Oncol 2006;24:512.

51. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221–8.

52. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006;12:6305s–8s.

Correspondence to: Mark Clemons, Breast Medical Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9.

E-mail: mark.clemons@uhn.on.ca